BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9864154)

  • 1. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.
    Taksin AL; Couedic JP; Dusanter-Fourt I; Massé A; Giraudier S; Katz A; Wendling F; Vainchenker W; Casadevall N; Debili N
    Blood; 1999 Jan; 93(1):125-39. PubMed ID: 9864154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes.
    Hofmann WK; Kalina U; Wagner S; Seipelt G; Ries C; Hoelzer D; Ottmann OG
    Exp Hematol; 1999 Mar; 27(3):395-400. PubMed ID: 10089900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders.
    Li Y; Hetet G; Kiladjian JJ; Gardin C; Grandchamp B; Briere J
    Br J Haematol; 1996 Jan; 92(1):60-6. PubMed ID: 8562412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome.
    Letestu R; Vitrat N; Massé A; Le Couedic JP; Lazar V; Rameau P; Wendling F; Vuillier J; Boutard P; Plouvier E; Plasse M; Favier R; Vainchenker W; Debili N
    Blood; 2000 Mar; 95(5):1633-41. PubMed ID: 10688818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compared effects of Mpl ligand and other cytokines on human MK differentiation.
    Vitrat N; Cohen-Solal K; Norol F; Guichard J; Cramer E; Vainchenker W; Wendling F; Debili N
    Stem Cells; 1998; 16 Suppl 2():37-51. PubMed ID: 11012176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.
    Yan L; Elkassar N; Gardin C; Briere J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():31-40. PubMed ID: 8951770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
    Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets.
    Debili N; Wendling F; Cosman D; Titeux M; Florindo C; Dusanter-Fourt I; Schooley K; Methia N; Charon M; Nador R
    Blood; 1995 Jan; 85(2):391-401. PubMed ID: 7529061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelofibrosis: experimental models and human studies.
    Taskin AL; Cohen-Solal K; Le Couedic JP; Abina MA; Villeval JL; Debili N; Casadevall N; Vainchenker W; Wendling F
    Stem Cells; 1998; 16 Suppl 2():155-64. PubMed ID: 11012187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF).
    Catani L; Gugliotta L; Campanini E; Mangianti S; Gibellini D; Baravelli S; Vianelli N; Lemoli RM; Tura S
    Br J Haematol; 1998 Jan; 100(1):207-18. PubMed ID: 9450813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential thrombocythaemia with mutation in
    Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
    J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.
    Kalina U; Hofmann WK; Koschmieder S; Wagner S; Kauschat D; Hoelzer D; Ottmann OG
    Exp Hematol; 2000 Oct; 28(10):1158-63. PubMed ID: 11027834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors.
    Debili N; Wendling F; Katz A; Guichard J; Breton-Gorius J; Hunt P; Vainchenker W
    Blood; 1995 Oct; 86(7):2516-25. PubMed ID: 7545460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow.
    Wang JC; Hashmi G
    Leuk Res; 2003 Jan; 27(1):13-7. PubMed ID: 12479847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of thrombopoietin and c-mpl expression in a child with essential thrombocythemia.
    Yoshida N; Ishii E; Koga N; Kamimura T; Miyazaki S
    Pediatr Hematol Oncol; 1998; 15(4):359-63. PubMed ID: 9658438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.
    Chaligné R; James C; Tonetti C; Besancenot R; Le Couédic JP; Fava F; Mazurier F; Godin I; Maloum K; Larbret F; Lécluse Y; Vainchenker W; Giraudier S
    Blood; 2007 Nov; 110(10):3735-43. PubMed ID: 17709604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cytokines on platelet production from blood and marrow CD34+ cells.
    Norol F; Vitrat N; Cramer E; Guichard J; Burstein SA; Vainchenker W; Debili N
    Blood; 1998 Feb; 91(3):830-43. PubMed ID: 9446643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia.
    Griesshammer M; Bangerter M; Schrezenmeier H
    Semin Thromb Hemost; 1997; 23(5):419-23. PubMed ID: 9387200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of erythroid differentiation and induction of megakaryocytic differentiation by thrombopoietin are regulated by two different mechanisms in TPO-dependent UT-7/c-mpl and TF-1/c-mpl cell lines.
    Goncalves F; Lacout C; Féger F; Cohen-Solal K; Guichard J; Cramer E; Vainchenker W; Duménil D
    Leukemia; 1998 Sep; 12(9):1355-66. PubMed ID: 9737683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.